DrugPatentWatch Database Preview

Details for Patent: 6,858,650

« Back to Dashboard

Which drugs does patent 6,858,650 protect, and when does it expire?

Patent 6,858,650 protects TOVIAZ and is included in one NDA.

This patent has seventy-eight patent family members in twenty-nine countries.

Summary for Patent: 6,858,650

Title:	Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:	The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s):	Meese; Claus (Monheim, DE)
Assignee:	Schwarz Pharma AG (DE)
Application Number:	10/130,214
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,858,650
Patent Claim Types: see list of patent claims	Compound; Formulation; Use;

Drugs Protected by US Patent 6,858,650

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	AB	RX	Yes	No				Y		TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	AB	RX	Yes	Yes				Y		TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

Foreign Priority and PCT Information for Patent: 6,858,650

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 55 190	Nov 16, 1999

PCT Information
PCT Filed	November 15, 2000	PCT Application Number:	PCT/EP00/11309
PCT Publication Date:	May 25, 2001	PCT Publication Number:	WO01/35957

International Family Members for US Patent 6,858,650

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	286872
Austria	337293
Austria	395056
Australia	2666701
Australia	778132
Brazil	0015610